News &amp; Updates

In patients with vulvar cancer, International Federation of Gynecology and Obstetrics (FIGO) stage >I is associated with regional and distant recurrences, suggests a study. Factors influencing local recurrence have not been identified.

FIGO stage >I predicts vulvar cancer recurrence

Drinking artificially sweetened beverages during pregnancy a risk factor for GDM

Pregnant women who frequently drink artificially sweetened beverages are at increased risk of gestational diabetes mellitus (GDM), according to a study.

Drinking artificially sweetened beverages during pregnancy a risk factor for GDM

eHealth intervention may lower gestational fat mass gain

A pragmatic multicomponent eHealth intervention during pregnancy appears to reduce gestational fat mass gain, particularly among women with normal weight and those who exceed gestational weight gain (GWG) guidelines, reports a study. This may have potential impacts on neonatal health outcomes.

eHealth intervention may lower gestational fat mass gain

Poor periconceptional glycaemic control magnifies pre-eclampsia risk in T1D

Women with type 1 diabetes (T1D) have an increased risk of developing pre-eclampsia during pregnancy, and this risk gets is commensurate with worsening blood sugar control around the time of conception, according to a study from Sweden.

Poor periconceptional glycaemic control magnifies pre-eclampsia risk in T1D

Real-world data support HPV vaccine efficacy in off-label age groups

09 Sep 2025 by

A prospective analysis demonstrates the effectiveness of HPV vaccination in reducing progression to biopsy-confirmed precancerous lesions and HPV persistence in a cohort of South Korean women in off-label age groups.

Real-world data support HPV vaccine efficacy in off-label age groups

Raludotatug deruxtecan shows efficacy signal in platinum-sensitive ovarian cancer

07 Sep 2025 by

The cadherin 6 (CDH6)-directed antibody–drug conjugate raludotatug deruxtecan elicits response in heavily pretreated patients with platinum-sensitive ovarian cancer while having a manageable safety profile, according to a subgroup analysis of an ongoing first-in-human phase I trial.

Raludotatug deruxtecan shows efficacy signal in platinum-sensitive ovarian cancer

07 Sep 2025

Thumbs up for rucaparib maintenance across prognostic subgroups of HRD-negative ovarian cancer

06 Sep 2025 by

Maintenance with the PARP inhibitor rucaparib after first-line platinum-doublet chemotherapy and cytoreductive surgery appears to reduce the risk of progression in the homologous recombination deficiency (HRD)-negative population of patients with advanced, high-grade ovarian cancer enrolled in the phase III ATHENA-MONO trial, no matter the prognostic factor.

Thumbs up for rucaparib maintenance across prognostic subgroups of HRD-negative ovarian cancer

Teens with dysmenorrhea prone to chronic pain as adults

Dysmenorrhoea in adolescence appears to contribute to an increased risk of chronic pain in adulthood, according to a study.

Teens with dysmenorrhea prone to chronic pain as adults

Selinexor maintenance shows consistent benefit in TP53wt endometrial cancer

06 Sep 2025 by

Selinexor maintenance therapy continues to show consistent clinical benefit in patients with TP53 wild-type (TP53wt) advanced or recurrent endometrial cancer, regardless of mismatch repair (MMR) status, according to the ENGOT-EN5/GOG-3055/SIENDO trial presented at ESMO Gyn 2025.

Selinexor maintenance shows consistent benefit in TP53wt endometrial cancer